AbbVie Inc.
AbbVie Announces Expected Third Quarter 2025 Acquired IPR&D and Milestones Expense
Summary
AbbVie Inc. announced that its reported GAAP and adjusted non-GAAP earnings for the third quarter of 2025 are expected to include acquired IPR&D and milestones expense of $2.7 billion, negatively impacting GAAP and adjusted non-GAAP diluted earnings per share by $1.50 each. The company has updated its full-year 2025 adjusted diluted earnings per share guidance to $10.38 - $10.58, and its third quarter 2025 guidance to $1.74 - $1.78, to reflect the impact of the acquired IPR&D and milestones expense. The final results are subject to completion of financial statement closing procedures.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement